Humanigen Inc. [NASDAQ: HGEN] traded at a low on 10/20/22, posting a -2.71 loss after which it closed the day’ session at $0.15. The company report on September 12, 2022 that Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Additional Clinical Sites Expected to Enroll CMML Patients in Australia.
Short Hills, New Jersey and Adelaide, South Australia–(Newsfile Corp. – September 12, 2022) – Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (“Humanigen”) and the South Australian Health and Medical Research Institute (“SAHMRI”) today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia (“PREACH-M”) study of lenzilumab in chronic myelomonocytic leukemia (“CMML”), a rare blood cancer, in patients with NRAS, KRAS, and CBL genetic mutations. The PREACH-M study will expand from the first two sites at the Royal Adelaide Hospital in Adelaide, Southern Australia and Austin Health-Austin Hospital in Heidelberg, Victoria to add up to 6 additional sites; one in Queensland, one in Western Australia, two sites in New South Wales, a site in Tasmania, and options being explored for an additional site in New Zealand.
The results of the trading session contributed to over 2656322 shares changing hands. Over the past one week, the price volatility of Humanigen Inc. stands at 7.25% while the volatility over the past one month is 11.74%.
The market cap for HGEN stock reached $15.46 million, with 103.66 million shares outstanding and 89.42 million shares in the current float. Compared to the average trading volume of 7.84M shares, HGEN reached a trading volume of 2656322 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Humanigen Inc. [HGEN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HGEN shares is $3.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HGEN stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. The new note on the price target was released on July 13, 2022, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another drop from $30 to $2, while Cantor Fitzgerald kept a Neutral rating on HGEN stock.
The Average True Range (ATR) for Humanigen Inc. is set at 0.02, with the Price to Sales ratio for HGEN stock in the period of the last 12 months amounting to 3.77.
How has HGEN stock performed recently?
Humanigen Inc. [HGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.71. With this latest performance, HGEN shares dropped by -6.97% in over the last four-week period, additionally sinking by -92.89% over the last 6 months – not to mention a drop of -97.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 34.72, with the RSI for the last a single of trading hit 35.45, and the three-weeks RSI is set at 34.00 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 0.2220, while it was recorded at 0.1590 for the last single week of trading, and 1.6714 for the last 200 days.
Humanigen Inc. [HGEN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Humanigen Inc. [HGEN] shares currently have an operating margin of -6474.88. Humanigen Inc.’s Net Margin is presently recorded at -6582.73.
Return on Equity for this stock declined to -2,165.43, with Return on Assets sitting at -339.62.
Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.
Earnings analysis for Humanigen Inc. [HGEN]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HGEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humanigen Inc. go to 12.50%.
Insider trade positions for Humanigen Inc. [HGEN]
There are presently around $3 million, or 14.70% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: VALIANT CAPITAL MANAGEMENT, L.P. with ownership of 6,888,607, which is approximately 0% of the company’s market cap and around 13.74% of the total institutional ownership; MURCHINSON LTD., holding 5,250,000 shares of the stock with an approximate value of $0.79 million in HGEN stocks shares; and VANGUARD GROUP INC, currently with $0.37 million in HGEN stock with ownership of nearly 1.062% of the company’s market capitalization.
Positions in Humanigen Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 29 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 1,835,098 shares. Additionally, 53 investors decreased positions by around 8,255,284 shares, while 15 investors held positions by with 11,952,118 shares. The mentioned changes placed institutional holdings at 22,042,500 shares, according to the latest SEC report filing. HGEN stock had 16 new institutional investments in for a total of 998,436 shares, while 30 institutional investors sold positions of 1,790,770 shares during the same period.